Karyopharm Therapeutics | KPTI - 판매 및 관리 비용





판매 및 관리 비용 변화 날짜
AbbVie USD 3.89B 325M 2025-12
Abbott USD 3.13B 125M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Incyte USD 390.41M 61.33M 2025-12
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.85B 215M 2025-12
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.44B 128M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Takeda JPY 282.78B 29.23B 2025-12
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
TG Therapeutics USD 50.73M 12.64M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Xencor USD 17.04M 70.74M 2025-12